Last Updated Jan 8, 2010 6:42 AM EST
The money comes in return for creating 918 jobs in the state. Put another way, each company that receives a tax break must create on average only 32 jobs. Among the beneficiaries:
- Biogen Idec (BIIB), Cambridge - $1.5 million
- Genzyme (GENZ), Cambridge/Framingham - $6 million
- Merrimack Pharmaceuticals, Cambridge - $1.5 million
- Sepracor, Marlboro - $750,000
For instance, Sepracor got a $3.9 million tax deal from Massachussetts late last year after promising to add 250 employees. Within months it had laid off 940 workers. Connecticut taxpayers paid $160 million for the privilege of having Pfizer (PFE) base its R&D operations in the state -- but after the Wyeth acquisition Pfizer axed 19,500 jobs and abandoned a planned New London site. And Bayer (BAY.DE) successfully held up Berkley, Calif., for $10 million in return for doing nothing more than staying in the city.
It happens on the national level too. Drug companies spend millions lobbying Congress to expand Medicare's prescription drug benefits, which is essentially free money for pharma.
Compare those actions with the words of Big Pharma's lobby group, PhRMA. PhRMA boss Billy Tauzin gave this speech in 2005:
This kind of research is possible for one reason, and one reason only â€" because of the miracle of the free market system, and its ability to pull together the needed resources.Those words may no doubt be true -- in theory. But in practice drug companies are happy to shelve the Ayn Rand rhetoric whenever there's a chance of getting a government handout.
... When you look at the facts, it's clear that the best engine for innovation is the free market. It ties together the capital -- that funds the research -- that creates the drugs -- that make it possible for children to survive leukemia, for people to live a lot longer with AIDS, and Alzheimer's sufferers to live a decent life for far more years than they would.
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Ohio Taxpayers Give Boehringer a $16M Bailout Package
- Pfizer's R&D Cuts Render Kelo v. New London Eminent Domain Case a Waste of Time
- Pfizer Closes Bridgewater Site; Clock Ticks on CT Tax Deal; Layoffs All Over
- UPDATED: On Tax Issues, Pfizer Plays Michigan Like a Violin
- Missouri Taxpayers Give Boehringer a $100K "Thank You" Check
- Bayer Wants Berkeley to Give It a $13M Tax Bailout
- Sanofi, Sepracor Keep Local Politicians in Thrall Over Taxes